Tuberculosis Therapeutics Market Outlook 2031
The global tuberculosis therapeutics market size was valued at USD 2.01 Billion in 2022 and is projected to reach USD 3.14 Billion by 2031, expanding at a CAGR of 5.09% during the forecast period, 2023–2031. The growth of the market is attributed to the increase in drug susceptible (DS) tuberculosis (TB), as well as an increase in multi-drug resistant (MDR) TB cases and increased R&D activities for novel drug development.
Tuberculosis (TB) is a highly infectious illness that affects the lungs. It has the potential to spread to other regions of your body, including the brain and spine. Mycobacterium tuberculosis is the bacteria that causes it. The virus that causes tuberculosis can be present in a person's body without causing symptoms.
Most people's immune systems are capable of containing germs, preventing them from replicating and causing disease. A person will have TB infection but not active disease in this situation. This is referred to as latent tuberculosis by doctors.
There is no chance of a latent infection spreading to another individual. A person with latent tuberculosis, on the other hand, still has to be treated. The body's ability to contain tuberculosis germs may be compromised.
When the immune system is weakened by sickness or the use of certain drugs, then TB is more likely to occur. When this occurs, the bacteria can multiply and create symptoms, leading to active tuberculosis. People who have active tuberculosis can transfer the infection to others. TB becomes active in 5–10% of persons with the infection if they do not receive medical treatment.
According to the CDC, roughly half of these patients advance within two to five years of contracting the virus. Anyone with a weakened immune system, anyone who initially got the infection in the last 2–5 years, elderly individuals and small children, people who use injectable recreational drugs, and those who have not received proper TB treatment in the past are at a higher risk of getting active TB.
A person with latent tuberculosis has no symptoms and no visible damage on a chest X-ray. A blood test or a skin prick test, on the other hand, will reveal that they are infected with tuberculosis.
A person with tuberculosis, on the other hand, may have a phlegmy cough, tiredness, a fever, chills, and a loss of appetite and weight. Symptoms usually increase with time, but they can sometimes go away and come back on their own. Although a person with latent tuberculosis has no symptoms, the infection can be detected by testing.
If someone has spent time with a person who has or is at risk of TB, has traveled to a country with high TB rates, or works in an environment where TB may be prevalent, they should request a tuberculosis test.
Patient’s therapy will be determined by the nature of your infection. If patient have latent tuberculosis, doctor will prescribe antibiotics to destroy the germs and prevent the infection from becoming active. Isoniazid, rifapentine, or rifampin may be given alone or in combination. Patient may be needed to take the medication for up to 9 months.
Active tuberculosis is also treated with a mix of medications. Ethambutol, isoniazid, pyrazinamide, and rifampin are the most frequent. Patient will have to take them for six to twelve months. There are two tests that can detect the presence of tuberculosis germs.
These tests include a tuberculosis skin test and a tuberculosis blood test. These tests, however, are unable to determine whether TB is active or latent. A sputum test and a chest X-ray may be recommended by the doctor to check for active TB illness.
TB is curable if caught early and treated with the right medicines. The appropriate antibiotic and duration of treatment will be determined by the patient's age and overall health, whether they have latent or active tuberculosis, the location of the infection, and whether the TB strain is drug resistant.
Tuberculosis Therapeutics Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of tuberculosis worldwide is projected to boost the market growth during the forecast period.
- Favorable government initiatives for spreading awareness regarding tuberculosis is expected to fuel the market growth during the forecast period.
- Increasing healthcare expenditure and increased number of hospitals & clinics are estimated to push the market growth during the forecast period.
- High price of second line treatment drugs is projected to hamper the market growth during the forecast period.
- Extensive focus on R&D for development of novel product or treatment with shorter period of treatment and technological advancements are projected to offer lucrative opportunities for the market players.
Scope of Tuberculosis Therapeutics Market Report
The report on the global tuberculosis therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Tuberculosis Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Disease Type (Active TB and Latent TB) and Therapy (First-Line Therapy and Second-Line Therapy)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Johnson & Johnson (J&J) Services; Lupin; Novartis AG; Macleods Pharmaceuticals Limited; Pfizer Inc.; Lupin Limited; and Otsuka Pharmaceutical Co., Ltd.
|
Tuberculosis Therapeutics Market Segment Insights
Diseases Segment Analysis
Based on diseases, the tuberculosis therapeutics market is bifurcated into active TB and latent TB. The active TB segment is expected to account for a key share of the market during the forecast period owing to increasing prevalence of drug susceptible (DS) and multi-drug resistant (MDR) TB cases.
Globally, 9 million individuals develop active tuberculosis each year, according to the Centers for Disease Control and Prevention (CDC). While active tuberculosis (ATB) is the main emphasis in this market, established economies with low TB risk but significant immigration flow and population mobility are focusing on latent TB infection (LTBI) therapy.
Therapy Segment Analysis
Based on therapy, the tuberculosis therapeutics market is bifurcated into first-line therapy and second-line therapy. The second-line therapy segment is expected to constitute a key share of the market during the forecast period owing to growing MDR TB prevalence, increased national tracking efforts, and global initiatives coordinated by WHO and the Global Drug Facility (GDF).
The demand for the use of second-line therapy has increased as the number of drug-resistant disease patients has increased. The segment's significant revenue share in the total market is due to the cost-intensive structure of MDR TB medicines.
Regional Outlook
On the basis of regions, the tuberculosis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is anticipated to dominate the market during the forecast period.
The regional market growth can be attributed to the disease's high prevalence, increased prevalence of HIV-TB co-infection, greater public knowledge of the dangers of drug non-compliance, and improved healthcare infrastructure. In terms of API production, China and India are major players in the APAC industry.
On the other hand, Europe and North America is expected to exhibit a rapid growth rate in the coming years. In Europe, there are nine countries classified as high-risk, with MDR and XDR TB rates on the rise. According to WHO, the number of new MDR-TB cases in the region is at an all-time high. The fundamental cause of the rise in drug-resistant forms of the disease is insufficient therapy.
Despite the low incidence and prevalence of DS tuberculosis in North America, a growing immigrant population necessitates a larger attention on LTBI screening programs. In the United States and Canada, where there is a significant percentage of immigrant population, efforts to stop the spread of the latent disease type have risen. This is expected to enhance the market for medicines to treat latent TB in the region.
Segments
The global tuberculosis therapeutics market has been segmented on the basis of
Disease Type
Therapy
- First-Line Therapy
- Second-Line Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the tuberculosis therapeutics market includes Johnson & Johnson (J&J) Services; Lupin; Novartis AG; Macleods Pharmaceuticals Limited; Pfizer Inc.; Lupin Limited; and Otsuka Pharmaceutical Co., Ltd.
Some of the key business strategies employed by companies includes such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
- In April 2019, Mylan, a pharmaceutical firm, partnered with the TB Alliance to market the Pretomanid medication for the treatment of pulmonary tuberculosis.
Request For Customization
Enquiry Before Buying
Speak With Analyst
